Cargando…

Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

Detalles Bibliográficos
Autores principales:	Kraeber-Bodéré, Françoise, Zweegman, Sonja, Perrot, Aurore, Hulin, Cyrille, Caillot, Denis, Facon, Thierry, Leleu, Xavier, Belhadj, Karim, Itti, Emmanuel, Karlin, Lionel, Bailly, Clément, Levin, Mark-David, Minnema, Monique C., Jamet, Bastien, Bodet-Milin, Caroline, de Keizer, Bart, Béné, Marie C., Avet-Loiseau, Hervé, Sonneveld, Pieter, Pei, Lixia, Rigat, Fabio, de Boer, Carla, Vermeulen, Jessica, Kampfenkel, Tobias, Lambert, Jérôme, Moreau, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890028/ https://www.ncbi.nlm.nih.gov/pubmed/36263839 http://dx.doi.org/10.3324/haematol.2021.280051

Ejemplares similares

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
por: Hulin, Cyrille, et al.
Publicado: (2021)

Treatment emergent peripheral neuropathy in the CASSIOPEIA trial
por: Fokkema, Cathelijne, et al.
Publicado: (2022)

FDG-PET in Follicular Lymphoma Management
por: Bodet-Milin, C., et al.
Publicado: (2012)

[(18)F]-Fludarabine for Hematological Malignancies
por: Barré, Louisa, et al.
Publicado: (2019)

Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?
por: Michaud-Robert, Anne-Victoire, et al.
Publicado: (2020)

Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
por: Moreau, Philippe, et al.
Publicado: (2020)

PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients
por: Bailly, Clément, et al.
Publicado: (2017)

Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials
por: Michaud-Robert, Anne-Victoire, et al.
Publicado: (2020)

Improvement of Radioimmunotherapy Using Pretargeting
por: Frampas, Eric, et al.
Publicado: (2013)

Pretargeting for imaging and therapy in oncological nuclear medicine
por: Bailly, Clément, et al.
Publicado: (2017)

Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials
por: Bailly, Clément, et al.
Publicado: (2016)

Incidental findings suggestive of COVID-19 in asymptomatic cancer patients undergoing 18F-FDG PET/CT in a low prevalence region
por: Pallardy, Amandine, et al.
Publicado: (2020)

Immuno-PET: Design options and clinical proof-of-concept
por: Lugat, Alexandre, et al.
Publicado: (2022)

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
por: Bailly, Clément, et al.
Publicado: (2019)

Interest of Pet Imaging in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2019)

Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma
por: Bailly, Clement, et al.
Publicado: (2017)

From a PMT-based to a SiPM-based PET system: a study to define matched acquisition/reconstruction parameters and NEMA performance of the Biograph Vision 450
por: Carlier, Thomas, et al.
Publicado: (2020)

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
por: Avet-Loiseau, Herve, et al.
Publicado: (2018)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy
por: Bailly, Clément, et al.
Publicado: (2014)

Inference of single-cell phylogenies from lineage tracing data using Cassiopeia
por: Jones, Matthew G, et al.
Publicado: (2020)

Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT
por: Carlier, Thomas, et al.
Publicado: (2013)

Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture
por: Bailly, Clément, et al.
Publicado: (2019)

Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial
por: Bodet-Milin, Caroline, et al.
Publicado: (2023)

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
por: Touzeau, Cyrille, et al.
Publicado: (2022)

New Developments in Myeloma Treatment and Response Assessment
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2023)

A pretargeting system for tumor PET imaging and radioimmunotherapy
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2015)

Immuno-PET for Clinical Theranostic Approaches
por: Bailly, Clément, et al.
Publicado: (2016)

ImmunoPET in Multiple Myeloma—What? So What? Now What?
por: Bailly, Clément, et al.
Publicado: (2020)

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
por: Corre, Jill, et al.
Publicado: (2020)

Specific features to differentiate Giant cell arteritis aortitis from aortic atheroma using FDG-PET/CT
por: Espitia, Olivier, et al.
Publicado: (2021)

Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases
por: Pichon, Baptiste, et al.
Publicado: (2020)

Tumor Immunotargeting Using Innovative Radionuclides
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2015)

Potential for Nuclear Medicine Therapy for Glioblastoma Treatment
por: Bailly, Clément, et al.
Publicado: (2019)

Sensitivity of pretargeted immunoPET using (68)Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with (18)FDG PET-CT
por: Foubert, Fanny, et al.
Publicado: (2018)

Challenges in Nuclear Medicine: Innovative Theranostic Tools for Personalized Medicine
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2014)

Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches
por: Bodet-Milin, Caroline, et al.
Publicado: (2019)

P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01
por: Bobin, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lv8usd04ru2q445feh41gkub3r